Gong Xu-Bo, Lu Xing-Guo, Xu Gen-Bo, Wu Xian-Guo, Wang Lin, Zhang Xiao-Hong, Zhu Lei, Wang Wei-Qin
Laboratory of Bone Marrow, Department of Hematology, Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310009, China.
Zhonghua Yi Xue Za Zhi. 2010 Jun 8;90(22):1531-6.
To explore the role of bone marrow (BM) imprint in the diagnosis of hematological diseases.
Between January 2002 and June 2008, a total of 3024 cases with BM smears, imprints and sections conducted simultaneously were recruited. There were 1667 males and 1357 females with a median age of 55 years old (range: 7 to 92). The cellularity on imprint and smear was evaluated with the standard cellularity on BM section. With the integrative diagnosis (including all examinations and clinical outcomes) as the standard, the diagnostic accuracy of hematological diseases were compared between BM imprint, smear and section groups. Another 79 cases of lymphoma and 114 cases of plasma cell myeloma (PCM) were selected for a correlation analysis of tumor cell infiltration patterns.
BM imprint contained hematopoietic and non-hematopoietic regions and cells retained integrated structure. The cellularity evaluation by imprint was superior to smear overall. In BM imprint group, the diagnostic accuracy for hypersplenism (n = 130), metastatic carcinoma (n = 67), refractory anemia with excess blasts, myeloproliferative neoplasm (n = 174), and PCM (n = 94) were better than smear group (96.9% vs 80.7%, 91.0% vs 76.1%, 92.6% vs 81.5%, 92.5% vs 76.4%, and 97.8% vs 92.6% respectively, all P < 0.05); And the diagnostic accuracy for megaloblastic anemia (n = 69), acute myeloid leukemia (n = 104), refractory cytopenia with unilineage dysplasia (n = 15), refractory cytopenia with multilineage dysplasia (n = 22), and lymphoplasmacytic lymphoma (n = 12) were higher than biopsy section group (100% vs 84.0%, 91.3% vs 74.0%, 86.7% vs 60.0%, 90. 9% vs 72.7%, and 66.6% vs 50.0% respectively, all P < 0.05); And the diagnostic accuracy for myelodysplastic/myeloproliferative neoplasm (n = 26) was higher than smear group (76.3%, P < 0.05) and biopsy section group (78.2%, P < 0.05). Excellent correlations existed between BM imprint and section of the patients with lymphoma or with PCM (r = 0.90, r = 0.78, both P < 0.05).
BM imprint contains the characteristics of both smear and section. BM imprint is superior to smear for an evaluation of cellularity. And it is also better than section for an analysis of cytological changes.
探讨骨髓印片在血液系统疾病诊断中的作用。
选取2002年1月至2008年6月期间同时进行骨髓涂片、印片及切片检查的3024例患者。其中男性1667例,女性1357例,中位年龄55岁(范围:7至92岁)。以骨髓切片的标准细胞密度来评估印片和涂片的细胞密度。以综合诊断(包括所有检查及临床结果)为标准,比较骨髓印片、涂片及切片组对血液系统疾病的诊断准确性。另外选取79例淋巴瘤及114例浆细胞骨髓瘤(PCM)患者进行肿瘤细胞浸润模式的相关性分析。
骨髓印片包含造血及非造血区域,细胞结构完整。总体而言,印片对细胞密度的评估优于涂片。在骨髓印片组中,对脾功能亢进(n = 130)、转移性癌(n = 67)、原始细胞过多的难治性贫血、骨髓增殖性肿瘤(n = 174)及PCM(n = 94)的诊断准确性优于涂片组(分别为96.9%对80.7%、91.0%对76.1%、92.6%对81.5%、92.5%对76.4%、97.8%对92.6%,均P < 0.05);对巨幼细胞贫血(n = 69)、急性髓系白血病(n = 104)、单系发育异常的难治性血细胞减少(n = 15)、多系发育异常的难治性血细胞减少(n = 22)及淋巴浆细胞淋巴瘤(n = 12)的诊断准确性高于活检切片组(分别为100%对84.0%、91.3%对74.0%、86.7%对60.0%、90.9%对72.7%、66.6%对50.0%,均P < 0.05);对骨髓增生异常/骨髓增殖性肿瘤(n = 26)的诊断准确性高于涂片组(76.3%,P < 0.05)及活检切片组(78.2%,P < 0.05)。淋巴瘤或PCM患者的骨髓印片与切片之间存在良好的相关性(r = 0.90,r = 0.78,均P < 0.05)。
骨髓印片兼具涂片和切片的特征。骨髓印片在评估细胞密度方面优于涂片,在分析细胞学变化方面也优于切片。